Market speculation over Bombay Stock Exchange’s possible entry into India’s flagship Nifty 50 has reignited investor interest, even as doubts remain over eligibility and upcoming index reshuffles.
Bloomberg reported that speculation over Bombay Stock Exchange’s possible entry into India’s flagship Nifty 50 has revived interest in the stock, as the exchange’s shares continue to draw attention ahead of any index review. The newsletter also said foreign investors have returned to Indian equities, with their five-day average of net purchases now running at more than three times the 20-day average, a sign that overseas appetite is improving even as higher oil prices and geopolitical tensions cloud the broader market outlook.
The Nifty 50 is one of India’s most closely watched benchmarks, covering 50 large companies across 13 sectors and tracking about 53.73% of the free-float market capitalisation of stocks listed on the National Stock Exchange, according to NSE and Nifty Indices. Managed by NSE Indices, it is calculated on a free-float market-capitalisation basis and underpins a range of financial products, including index funds, futures and options.
But industry sources cited by NDTV Profit said BSE is not part of the NSE 100 and therefore does not meet the current eligibility rules for Nifty 50 inclusion. That has cast doubt on market talk that the exchange could replace Wipro in an upcoming reshuffle, even as traders continue to price in the possibility of changes to the benchmark’s line-up.
The debate comes after the Nifty 50’s last semi-annual reshuffle, which took effect on September 30, 2025, when InterGlobe Aviation, the owner of IndiGo, and Max Healthcare Institute entered the index, replacing Hero MotoCorp and IndusInd Bank, according to ICICI Direct and Livemint. Nuvama Institutional Equities estimated that the additions could draw hundreds of millions of dollars in passive inflows, a reminder of how powerful benchmark membership can be for share demand.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
